0.00
—
Close of 5 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MabCure
Its shares trade under the ticker MBCI. It has been listed since 23 July 2007. In the fiscal year to 31 December 2011, it reported revenue of $500,000 and a net loss of $12.5m. At that date it held total assets of $4.8m and shareholders' equity of $3.9m.
MabCure, Inc. develops novel diagnostics. The company employs 3 full-time employees The company went IPO on 2007-07-23. The firm is engaged in the business of developing and commercializing its antibody technology for the early detection of cancer and for the creation of therapeutics against cancer. The firm originally was in the business of developing a detergent for removing pesticides from fruits and vegetables. During the year ended December 31, 2011, the Company has not generated any revenue.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Jul 2007
- Employees
- 3
Leadership
Pay as last reported
- DR. Amnon GonennePresident, Chief Executive Officer, since 2012$180,026
- Dr. Charles TackneyChief Scientific Officer, Director, since 2012$110,617
- Mr. Dov WeinbergChief Financial Officer, since 2012
- Ms. Vered CaplanDirector, since 2012
- Dr. David FrankIndependent Director, since 2009
- Mr. Ron KalfusChief Financial Officer, since 2008$168,291
- Mr. Gad BerdugoIndependent Director, since 2010
- Dr. Elisha OrrExecutive Vice President, Chief Scientific Officer, since 2010$109,209
- Itshak ZivanDirector, since 2008
- Mr. Martin BajicChief Financial Officer, Principal Accounting Officer, Treasurer, since 2008
- Mr. Steven KatzDirector, since 2008
- Yapp Moi LeePresident, Chief Executive Officer, Director, since 2008
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MabCure Inc has a team of highly experienced researchers and scientists, enabling them to develop novel therapeutic antibodies.
- The company holds several patents for their antibody technology, giving them a competitive advantage in the market.
- MabCure Inc has established partnerships with leading pharmaceutical companies, allowing for collaboration and access to additional resources.
Weaknesses
- The company heavily relies on external funding sources, which may lead to financial instability if funding becomes limited.
- MabCure Inc currently lacks a diverse product portfolio and is solely focused on therapeutic antibodies, limiting their potential revenue streams.
- There is a lack of brand recognition for MabCure Inc, making it challenging to compete with more established companies in the market.
Opportunities
- The increasing demand for targeted and personalized therapies presents an opportunity for MabCure Inc to expand their market presence.
- Collaborating with academic institutions and research organizations can enhance MabCure Inc's research capabilities and accelerate drug development.
- The growing prevalence of chronic diseases offers a potential market for MabCure Inc's innovative antibodies.
Threats
- The competitive landscape in the biopharmaceutical industry is intense, with other companies also developing antibody-based therapies.
- Regulatory requirements and lengthy approval processes pose a challenge to the timely commercialization of MabCure Inc's products.
- Market uncertainties and economic fluctuations may impact the willingness of healthcare providers to invest in new therapies, affecting MabCure Inc's market opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.